Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY5R | Q15761 | 4/20 | 0.45 |
| ▸ | HTR2C | P28335 | 2/20 | 0.40 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.40 |
| ▸ | CTSC | P53634 | 1/20 | 0.39 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.39 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
| ▸ | DPP4 | P27487 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6820680 | 0.98 | NPY5R (0.44) | NPY5RHTR2CAVPR1ACTSCAKR1A1 | |
| SCHEMBL738397 | 0.88 | AVPR1A (0.50) | NPY5RHTR2CAVPR1AMAPTSIGMAR1 | |
| Hydrochloric Acid SCHEMBL6820620 | 0.87 | AVPR1A (0.49) | NPY5RHTR2CAVPR1AMAPTSIGMAR1 | |
| SCHEMBL29922364 | 0.83 | NPY5R (0.43) | NPY5RAVPR1AAKR1A1AKR1B1MAPT | |
| SCHEMBL3839131 | 0.82 | AVPR1A (0.50) | NPY5RHTR2CAVPR1AAKR1A1AKR1B1 | |
| SCHEMBL18373156 | 0.82 | NPY5R (0.45) | NPY5RHTR2CAVPR1ACTSCMAPT | |
| SCHEMBL5136522 | 0.81 | SIGMAR1 (0.42) | NPY5RAVPR1ACTSCSIGMAR1 | |
| Hydrochloric Acid SCHEMBL6819610 | 0.81 | AVPR1A (0.49) | AVPR1ACTSCMAPTSIGMAR1 | |
| SCHEMBL4367569 | 0.79 | AVPR1A (0.48) | NPY5RAVPR1AAKR1B1SIGMAR1 | |
| SCHEMBL29674557 | 0.79 | SIGMAR1 (0.54) | NPY5RAVPR1ASIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11414429-B2 | Compound or pharmaceutically acceptable salt thereof | RIKEN (JP) | 2022-08-16 | — | — | US | disclosed |
| EP-3480198-B1 | NOVEL COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | RIKEN (JP) | 2021-05-05 | — | — | EP | disclosed |
| US-20200172554-A1 | NOVEL COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | RIKEN (JP) | 2020-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11414429-B2 | Compound or pharmaceutically acceptable salt thereof | DPP8, DPP7, AZI2 | NPY5R 247/4885HTR2C 1183/4885AVPR1A 168/4885 |
| US-20200172554-A1 | NOVEL COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | DPP8, DPP7, AZI2 | NPY5R 259/4885HTR2C 1053/4885AVPR1A 158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.